Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial

AIMS/HYPOTHESIS: Semaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes. Its effects on first- and second-phase insulin secretion and other measures of beta cell function and glycaemic control were assessed. METHODS: In this single-centre, double-blind,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kapitza, Christoph, Dahl, Kirsten, Jacobsen, Jacob B., Axelsen, Mads B., Flint, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491562/
https://www.ncbi.nlm.nih.gov/pubmed/28526920
http://dx.doi.org/10.1007/s00125-017-4289-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491562/
https://www.ncbi.nlm.nih.gov/pubmed/28526920
http://dx.doi.org/10.1007/s00125-017-4289-0

Ejemplares similares